Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients; 80% ORR ...

Cancer remains one of the most critical global public health challenges, exerting profound social, economic, and clinical ...

Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

Scientists are exploring dandelion root extract's potential against colorectal cancer. Lab studies show it selectively ...

Ascentage Pharma will host a Chinese (Mandarin) language investor webcast with Q&A at 9:00 pm EST on December 11, 2025 / ...

Soluble TAM receptors (sTAMs) could serve as biomarkers for RA, indicating disease activity, severity, and prognosis, though standardized detection methods are needed. TAM receptors could emerge as ...

Cothera Bioscience’s zotiraciclib for treatment of recurrent high-grade glioma receives US FDA fast track designation: San Mateo, California Friday, November 28, 2025, 12:00 Hrs ...

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic β-cells.

Sonrotoclax has received FDA priority review for relapsed or refractory mantle cell lymphoma, indicating potential substantial treatment improvement. The BGB-11417-201 study demonstrated significant ...